Testa vår nya webbplats och uppdaterade nyhetsrum för att ta del av aktuella nyheter, rapporter och mycket mer.

Eevia Health Plc launches a new dietary supplement ingredient, Feno-Cerasus™, for cognitive health at a key industry trade show, Supply Side West in Las Vegas, US

Eevia Health has developed a new plant extract with product benefits for cognitive health and improved sleep. The new product, Feno-Cerasus™, is launched today at a major trade show in Las Vegas, US, the Supply Side West. The new ingredient is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the new products, including sleep quality and quantity, memory, as well as stress, and cortisol levels.

The main health benefit Eevia Health is promoting is improved cognitive function. Tart cherry has one clinical study with 37 subjects showing a positive effect on cognitive performance. Another four clinical studies with 63 subjects documented positive outcomes in sleep quality parameters. From PubMed 10/2022 one can also observe that 39 clinical studies have been published in peer-reviewed journals. Tart Cherries have been studied for Muscle recovery (15 studies, 280 subjects), Metabolic health (8 studies, 180 subjects), Cardiovascular health (5 studies, 150 subjects), Antioxidant properties in clinical studies (2 studies, 59 subjects), and positive results also in pain (2 studies, 108 subjects). Eevia Health's recent strategic focus on cellular recycling also is supported as the tart cherry has preclinical evidence of autophagy induction via AMPK signal pathway and anti-inflammatory properties via Sirtuin6 activation of cyanidin, which has been confirmed in in-vitro studies.

Eevia's manufacturing also ensures sustainability with the lowest Product Carbon Footprint (PCF) known in the industry. The Feno-Cerasus is organically certified under NOP, Euroleaf, Ecocert, JAS, and other standards. It is standardized to 10% Anthocyanins including anthocyanins with cyanidin-3-glucoside and cyanidin-3-rutinoside. Eevia Health's superior extraction and purification technology provide for a superior bioactive and nutritional profile. Feno-Cerasus™ is high on other polyphenols with a natural spectrum of polyphenolic compounds. It is a non-GMO, gluten-free, vegan ingredient with an excellent taste profile, highly suitable for gummies and other applications. Feno-Cerasus™ Organic is a superior standardized product with superior bioactive content available benefits 

"We are pleased to offer a new anthocyanin extract for cognitive health. The maintenance of cognitive health is a growing area for consumers. Eevia Health already has customer interest. The product will have perhaps the highest concentration of anthocyanins in the industry, while providing also a whole spectrum of other health-beneficial polyphenols as well." says Petri Lackman, CTO of Eevia Health.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc  
Email: [email protected]  
Telephone: +358 400 22 5967                     

This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on November 3rd, 2022, at 1:40 CEST.    


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on [email protected]  

Nerladdningsbara filer

Eevia Health Plc receives a USD 200K sales order for Feno-Sambucus™ 7 Organic

Eevia Health ("Eevia" or "The Company") received a sales order from a US customer for the elderberry extract Feno-Sambucus™ 7 Organic for a value of just over USD 200k or EUR 187k.


Stein Ulve, the Chief Executive Officer (CEO) of Eevia Health Plc, ("Eevia" or "The Company") has sold 112 782 shares in The Company to Harri Salo, the Chief Manufacturing Officer (CMO) of Eevia.

CORRECTION Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product

Due to a misjudgement, the MAR label was added to the original press release. The press release did not contain any insider information or other reason for the MAR label. This press release is a correction without the MAR label. 

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.

Eevia Health Plc receives a 150 KSEK / 13 KEUR sales order for a Bilberry extract product

Eevia Health Plc ("Eevia" or "The Company") has received a 13 KEUR sales order for Bilberry extract from its customer in South-Korea.

Last day of trading in paid subscription shares (Swedish: BTA) in Eevia Health Plc

Eevia Health Plc's ("Eevia" or "the Company") preferential rights issue has now been registered with the Finnish Trade Register. Paid Subscription Shares (Swedish: BTA) will thus be replaced by ordinary shares. The last day for trading with BTA on Spotlight Stock Market is 22 December 2022, and new shares are expected to be booked into the respective custodian/VP account on 29 December 2022.


Stein Ulve, the CEO of Eevia Health Plc, ("Eevia" or "The Company"), subscribed for 489 996 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed. Stein Ulve had 1 907 500 subscription rights, but he subscribed for 489 996 shares. Consequently, he was diluted under the flagging threshold of 10%.


Eevia Health Plc ("the Company" or "Eevia") has become aware that Marizoe Actives S.L. from Madrid, Spain has subscribed for 1 517 459 shares in the preferential rights issue, which Eevia concluded on November 17th. The equity issue was for 14 376 015 shares and was fully subscribed, leading to a new total of shares of 30 349 371. Marizoe Actives S.L. had no shares before the issue and with the subscription, Marizoe has 5.01% of the new outstanding shares.

Eevia Health Plc received small initial sales order for Feno-Sambucus™ from Australia

Eevia Health ("Eevia" or "The Company") received a start order for the Feno-Sambucus™ worth SEK 110 000 from its Australian distributor Ingredient Plus. The order is a new start order for an Australian brand owner.

Eevia Health Plc receives a 445 KSEK / 41 KEUR sales order for a Bilberry extract product

Eevia Health Plc's ("Eevia" or "The Company") has received a 41 KEUR sales order for Bilberry extract from its distributor in France Natural Ingredients.

Eevia Health Plc commissions new analytical equipment for analyzing anthocyanins and polyphenols

Eevia Health has commissioned a new High-Performance Liquid Chromatography (HPLC) analytical equipment from Shimadzu, which significantly increases the capacity to undertake analyses of polyphenols.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted